The successful employment of Brentuximab Vedotin to a patient with peritoneal dialysis: A case report

Brentuximab Vedotin, an antibody-drug conjugate targeting CD30, has been widely used in treating systemic anaplastic large-cell lymphoma and primary cutaneous anaplastic large-cell lymphoma. Despite its extensive use, information on its use in patients with end-stage renal disease is limited. This case report illustrates a 75-year-old male undergoing daily peritoneal dialysis, diagnosed with primary cutaneous anaplastic large-cell lymphoma. Due to extensive lesions, the patient opted for Brentuximab Vedotin following an exhaustive discussion. Remarkably, the treatment resulted in the complete resolution of cutaneous lesions, which was confirmed by a subsequent negative PET scan, indicating the absence of malignancy. Throughout the treatment course, the patient reported only weakness as a side effect, which was compounded by an acute COVID-19 infection at that time. This case report underscores the potential application of Brentuximab Vedotin in patients undergoing peritoneal dialysis, a population previously excluded, thus providing another promising therapeutic option for this particular population.